Compare BTMD & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTMD | LUNG |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 57.9M |
| IPO Year | 2021 | 2020 |
| Metric | BTMD | LUNG |
|---|---|---|
| Price | $2.22 | $1.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $2.83 | ★ $5.38 |
| AVG Volume (30 Days) | 303.3K | ★ 326.3K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | 7.64 |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $192,219,000.00 | $90,497,000.00 |
| Revenue This Year | $2.03 | $2.48 |
| Revenue Next Year | $6.58 | $18.46 |
| P/E Ratio | $3.03 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $1.27 | $1.13 |
| 52 Week High | $4.75 | $5.46 |
| Indicator | BTMD | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 69.22 | 40.47 |
| Support Level | $2.02 | $1.27 |
| Resistance Level | $2.79 | $1.64 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 85.39 | 10.96 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.